User login
Key clinical point: The incidence rate of squamous cell carcinoma (SCC) was extremely low and, hence, of minimal public health concern in patients with non-SCC breast cancer (BC) or carcinoma in situ who underwent implant-based reconstruction.
Major finding: Only 1 woman was diagnosed with SCC after 52 months of BC diagnosis. The incidence rate of SCC after implant-based reconstruction was extremely low (2.37 per million person-years) and was not significantly higher in women with BC than in the general population (standardized incidence ratio 2.33; 95% CI 0.06-13.0).
Study details: Findings are from a cohort study including 56,785 women with BC or carcinoma in situ who underwent cancer-directed mastectomy with implant reconstruction.
Disclosures: This study was supported by the US National Cancer Institute. Some authors declared receiving personal fees or grants or having other ties with several sources.
Source: Kinslow CJ et al. Risk of squamous cell carcinoma of the breast following postmastectomy implant reconstruction in women with breast cancer and carcinoma in situ. JAMA Surg. 2023 (Apr 19). Doi: 10.1001/jamasurg.2023.0262
Key clinical point: The incidence rate of squamous cell carcinoma (SCC) was extremely low and, hence, of minimal public health concern in patients with non-SCC breast cancer (BC) or carcinoma in situ who underwent implant-based reconstruction.
Major finding: Only 1 woman was diagnosed with SCC after 52 months of BC diagnosis. The incidence rate of SCC after implant-based reconstruction was extremely low (2.37 per million person-years) and was not significantly higher in women with BC than in the general population (standardized incidence ratio 2.33; 95% CI 0.06-13.0).
Study details: Findings are from a cohort study including 56,785 women with BC or carcinoma in situ who underwent cancer-directed mastectomy with implant reconstruction.
Disclosures: This study was supported by the US National Cancer Institute. Some authors declared receiving personal fees or grants or having other ties with several sources.
Source: Kinslow CJ et al. Risk of squamous cell carcinoma of the breast following postmastectomy implant reconstruction in women with breast cancer and carcinoma in situ. JAMA Surg. 2023 (Apr 19). Doi: 10.1001/jamasurg.2023.0262
Key clinical point: The incidence rate of squamous cell carcinoma (SCC) was extremely low and, hence, of minimal public health concern in patients with non-SCC breast cancer (BC) or carcinoma in situ who underwent implant-based reconstruction.
Major finding: Only 1 woman was diagnosed with SCC after 52 months of BC diagnosis. The incidence rate of SCC after implant-based reconstruction was extremely low (2.37 per million person-years) and was not significantly higher in women with BC than in the general population (standardized incidence ratio 2.33; 95% CI 0.06-13.0).
Study details: Findings are from a cohort study including 56,785 women with BC or carcinoma in situ who underwent cancer-directed mastectomy with implant reconstruction.
Disclosures: This study was supported by the US National Cancer Institute. Some authors declared receiving personal fees or grants or having other ties with several sources.
Source: Kinslow CJ et al. Risk of squamous cell carcinoma of the breast following postmastectomy implant reconstruction in women with breast cancer and carcinoma in situ. JAMA Surg. 2023 (Apr 19). Doi: 10.1001/jamasurg.2023.0262